KORTUC Inc. Clinches $20M Series B Funding to Revolutionize Radiotherapy with Hydrogen Peroxide Injection Innovations

KORTUC INC. is excited to announce a major funding milestone, having raised $20,000,000 to further accelerate its groundbreaking work in the field of radiotherapy enhancement. This new injection of capital represents a significant vote of confidence from investors in the company’s innovative approach to cancer treatment. KORTUC has pioneered an advanced drug that maximizes the effectiveness of radiotherapy by directly injecting Hydrogen Peroxide into tumors, a method that sensitizes them to radiation. This approach addresses a central challenge in conventional radiotherapy—namely, the difficulty in ensuring that tumors are sufficiently responsive to treatment—by targeting the tumor microenvironment in a way that enhances the overall therapeutic impact. The funds raised will be dedicated to scaling up clinical trials and expanding research and development efforts, ensuring that this promising treatment can be rigorously tested and refined for widespread clinical use. Moreover, KORTUC plans to invest in advanced manufacturing capabilities and strategic partnerships to streamline the production process and enhance distribution channels, ultimately making this emerging therapy accessible to a broader population of patients in need. With a commitment to revolutionizing cancer treatment modalities and improving patient outcomes, KORTUC’s innovative strategy stands poised to reshape the landscape of radiotherapy. This funding round is a pivotal step in achieving that mission, fostering further innovation and collaboration in the medical community, and bringing renewed hope to those battling cancer worldwide.